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Monoamine oxidase (MAO)-A and MAO-B are FAD-contaming mitochondrial enzymes which catabolize biogemc and xenobiotic amines. The 
N-terminal regions of both forms of MAO contain an ADP-binding consensus sequence found in several dinucleotide-dependent enzymes, but 
otherwise show remarkable sequence differences. In order to investigate whether the N-termmal region of MAOs participates in the different 
catalytic properties and inhibitor specificities exhibited by MAO-A and MAO-B, we constructed chimeric A/B forms and expressed them in a human 
embryonic kidney cell line (293 cells). The MAO-A chimertc form containing the N-terminus (36 ammo acids) of MAO-B and the B chimera having 
the first 45 amino acid sequence of MAO-A were both catalytically acttve. Compared to the respective wild-type form, they did not show any 
significant difference in their catalytic properties (K,. /ccat) towards the substrates tested or m their sensitivity towards inhibitors. This indicates 
that the N-terminal region of the two tsoenzymes IS not mvolved in the different specificities of MAO-A and MAO-B. Substitution of Cys-397 of 
MAO-B, i.e. the residue covalently anchoring FAD. with an Ala or a His residue resulted in the total loss of enzymatic activity, suggesting that 
the covalent coupling of FAD to MAO occurs specifically at the -SH group of cysteine. 
Monoamine oxidase; FAD-binding domain; Chtmeric enzyme: Sue-directed mutagenesis: 293 Cell line 
1. INTRODUCTION 
The mitochondrial monoamine oxidases (MAO, EC 
1.4.3.4., flavin-containing), MAO-A and MAO-B, are 
enzymes involved in the metabolism of several amines 
including neurotransmitters, trace amines, and xenobi- 
otics. The two isoenzymes are differently localized in 
various tissues, show different specificity towards sub- 
strates, and are selectively blocked by various inhibitors 
[l]. In humans, the two proteins, encoded by distinct 
genes [2], exhibit a high degree of sequence identity 
(about 70%) [3,4]. Comparison of the primary se- 
quences of MAO-A and -B with those of other known 
proteins revealed little sequence homology except for 
the N-terminal sequence of both isoenzymes (residues 
Asp-l 5 to Glu-43 and Asp-6 to Glu-34 for MAO-A and 
-B, respectively) which presents an ADP-binding se- 
quence fingerprint found in several NAD- and FAD- 
dependent enzymes [6]. This region, predicted to fold 
into a /?@I conformation and which is most often pres- 
ent at the protein N-termini, interacts with the ADP 
moiety of NAD and FAD. As previously pointed out 
[7], whereas MAO-A and MAO-B are identical for the 
amino acids which constitute this dinucleotide-binding 
site, remarkable sequence differences, with some posi- 
tions conserved in MAOs of the animal species studied 
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so far, are present in the N-terminal regions of MAO-A 
and MAO-B. This observation has prompted the hy- 
pothesis that these differences in sequence may be at 
least partly responsible for the specificity of the two 
isoforms towards various substrates and selective MAO 
inhibitors [l]. In order to investigate this, we set up an 
expression system for MAOs in a human cell line and 
we constructed chimeric A and B forms carrying the 
N-terminal sequence of the other isoenzyme. In addi- 
tion, we report on the effect on the enzymatic activity 
of the substitution of Cys-397 of MAO-B, i.e. the resi- 
due covalently anchoring FAD, with an alanine or his- 
tidine. These experiments were carried out in order to 
investigate whether the coupling of FAD in MAO has 
a strict requirement for cysteine to have enzymatic ac- 
tivity. 
2. MATERIALS AND METHODS 
2.1. Mutertuls 
[‘H]Ro 41-1049 (spec. act. 30.8 Ci/mmol; 1 Ci = 37 GBq) and 
[‘Hllazabemtde ([‘H]Ro 19-6327, spec. act. 17 Ci/mmol) were synthe- 
sized by Dr. H. Harder (Isotope Synthesis Department, F. Hoffmann- 
La Roche. Basel). [‘4C]5-hydroxytryptamine (5-HT. 56 mCi/mmol) 
and [V]phenylethylamine (PEA, 50.8 mCi/mmol) were purchased 
from Amersham (Little Chalfont. UK) and New England Nuclear 
(Boston. MA, USA), respectively. All other chemicals were of analyt- 
ical grade and obtained from various sources. 
2.2. Construction of chtmera hetwven MAO-A and MAO-B and mut- 
qenesu 
Since the MAO-B cDNA sequence has already a Snrul restriction 
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site at amino acid position Arg-36 [3], a unique restriction site for 
endonuclease SmaI was introduced into the pCMV-MAO-A cDNA 
sequence at the corresponding amino acid position Arg-45 by site- 
directed mutagenesis using an in vitro mutagenesis kit system (Amer- 
sham). The presence of the introduced restriction site was proven by 
restriction analysis of isolated plasmid DNA from randomly selected 
colonies. 
The plasmids pCMV-MAO-A-SmaI and pCMV-MAO-B were di- 
gested by endonuclease SmaI. The resulting C-terminal fragments 
were gel purified and ligated into the &&digested and gel-purified 
pCMV-MAO-B and -MAO-A vectors, respectively. The chimeric 
MAO constructs, containing the N-terminal part of the other isoen- 
zyme, were as follows: MAO-(A45)B; MAO-(B36)A (see Fig. 1). 
For transfection, the native (wild-type) and hybrid constructs were 
purified by alkaline lysis and cesium chloride density gradient centrif- 
ugation. 
2.3. Engineering of MAO-B Cys-FAD mutations 
A 1,670 bp MAO-B EcoRIlHindIII fragment was subcloned into 
the vector pCMV. Site-directed mutagenesis was performed by PCR 
(polymerase chain reaction) with overlapping mismatch primers ac- 
cording to the procedure used by Higuchi et al. [8]. The resulting 
changes of the amino acids were as follows: Cys-397 --f His: Cys-397 
-+ Ala. 
The mutagenesis was confirmed by DNA sequence analysis of the 
entire PCR-fragment with appropriate oligonucleotide primers. The 
mutant DNAs were digested with EcoRIlHindIII and subcloned into 
the vector pCMV for expression in the mammalian cells. The vector 
pCMV was composed of an SV40 origin, the human cytomegalo virus 
promoter, and the Ml3 origin of replication which can be used for 
sequencmg and mutagenesis. 
2.4. E.rpression of constructs m 293 cells 
For transfection, 293 cells (human embryonic kidney cells, ATCC 
CRL 1573) were seeded in a concentration of 2.5 x lo5 cells/ml and 
grown for 24 h at 37°C under 5% COz, m MEM+ (Gibco-BRL, 
Gaithersburg, MD, USA) with the addition of 20 mM HEPES. 10% 
fetal calf serum, 2 mM L-glutamine, 100 IU/ml penicillm. 100 bug/ml 
streptomycin. The subconfluent cells were then washed with DMEM 
(Gibco-BRL) and incubated in the same medium with a mixture of I 
pug of expression vector and 5 pg of Transfectam (IBF Biotechnics. 
Villeneuve-La Garenne, France) per ml, for 2 h at 37°C under 5% CO, 
[9]. The cells were grown for another 48 h in MEM+ and then col- 
lected, washed twice with PBS, pH 7.4, and frozen as a cell pellet, 
Transfection was performed with the native MAO-A and -B con- 
structs, both in sense and antisense orientation (mock-transfection) to 
the promoter, and with the chimera or mutated constructs described 
above. 
2.5. Enzyme activity determination and radioligand binding 
Ahquots of the transfected cells were thawed and gently homoge- 
nized in 0.5 ml of 20 mM Tris, pH 8.0. containing 0.5 mM EGTA and 
0.5 mM phenylmethanesulfonyl fluoride. Enzymatic activity was as- 
sayed radiochemically as previously described [IO]. For kinetic analy- 
sis, aliquots (5520 ~1) of the homogenates were incubated (10 min at 
37°C) in the presence of various concentrations of radiolabeled sub- 
strates. Experimental curves were fitted to Michaelis-Menten kinetics 
using a computer program (ENZFITTER, Elsevier-Biosoft, Amster- 
dam, The Netherlands). Inhibition experiments were performed by 
premcubating (15 mm at 37°C) the cell homogenates m the presence 
of various inhibitors. MAO-A and MAO-B activities were then as- 
sayed after the addition of 106 PM [14C]5-HT or 1 PM [‘+‘C]PEA, 
respectively, and by incubatmg for further 10 min at 37°C. 
The amount of wild-type MAO-A and MAO-(B36)A mutant active 
centers was determined by [3H]Ro 41-1049 binding [ll]; [‘Hllaza- 
bemide was used for titration of wild-type MAO-B and its (A45)B 
chimera [12]. Radioligand binding saturation curves were analyzed 
usmg the LIGAND computer program [13]. 
Protein content was determined by the Pierce BCA Protem Assay 
(Rockford, IL. USA) according to the manufacturer’s instructions. 
2.6. Immunoblot analysis 
Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS- 
PAGE) was performed on slab gels (12.5% monomer concentration) 
according to Lammli [14] and proteins were blotted on nitrocellulose 
sheets as previously described 1151. Blots were then incubated over- 
night with specific monoclonal antibodies against MAO-A (MAO 
A-6C1 I-5C7, generously provided by Prof. C.W. Abell, University of 
Texas, Austin, TX, USA) or against MAO-B (MAO B-1C2 [16], hy- 
bridoma cell line obtained from ATCC, HB 8176). Immunoreactive 
bands were then detected, after incubation with peroxidase-linked 
sheep anti-mouse antibodies, by the Amersham enhanced chemolu- 
minescence (ECL) detection system. 
3. RESULTS 
3.1, Expression of wild-type and chimeric MAO forms in 
293 cells 
Untransfected 293 cells showed relatively low levels 
of endogenous MAO activity which was of the A type. 
The K,,, and V,,,,, values for 5-HT were 190 ? 35 PM 
and 4.90 pmols-‘.mg protein-‘, repectively. The 
amount of endogenous MAO-A, determined by [3H]Ro 
41-1049 binding, was 0.43 ? 0.05 pmol/mg protein. 
Cells mock- transfected with MAO-A and -B antisense 
constructs did not show differences in enzymatic activ- 
ity when compared to untransfected cells. 
To investigate the properties of the recombinant wild- 
type MAO-A and -B and their respective forms with the 
N-terminal sequence of the other isoenzymes, the corre- 
sponding cDNAs were transiently expressed in 293 
cells. The kinetic constants of the wild-type and chim- 
eric forms were then determined in the cell homogenates 
using the substrates [14C]5-HT and [‘4C]PEA, preferred 
by MAO-A and MAO-B, respectively. Both the wild- 
type and chimeric MAOs were found to be expressed in 
a catalytically active form. The observed kinetic para- 
meters are summarized in Tables 1 and II. As can be 
seen, the K,,, values of the two substrates for recombi- 
nant MAO-A and MAO-B were in the range of those 





I MAO-(A45)B F,,!,, ) 
___ 
MAWWA ms,, 
Fig. 1. Diagram of constructs of MAO-A and MAO-B and their A/B 
chimera. The wild-type and the chimeric forms are schematically sum- 
marized: shaded and empty bars corresponds to MAO-A and MAO-B 
sequences, respectively. The numerals shown below the bars are the 
position of amino acids in each form. 
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Table I Table III 
Kinetic constants of 5-HT deamination by wild-type MAO-A and by 
its (B36)A chimer 
Kinetic parameters of [‘H]Ro 41-1049 and [jH]lazabemide binding to 
293 cells transfected with wild-type and chimeric MAOs 
& V lnax k cat kc,JKn 
C&M) (pmols-‘.mg (s-j) (M-‘Y’) 
prot.) 
MAO-A wild-type 94.0+ 7.8 52.2f 1.8 12.2 f 0.4 1.3 x lo5 
MAO-(B36)A 65.2 f 2.5 52.1 k4.5 12.6+ 1.1 1.9 x lo5 
Mean + S.E.M. of 34 experiments performed in duplicate. 
e.g. [17]). The two A/B chimeric MAO forms did not 
significantly differ from the respective wild-type en- 
zymes in their affinities for 5-HT and PEA. The same 
was true for the values k,,, (calculated from I’,,,/ 
[MAO], see below) and, consequently, for the apparent 
second-order ate constants (&J&J, which were virtu- 
ally identical in the wild-type and the respective chim- 
eric enzymes. In the case of MAO-B and MAO-(A46)B 
the kinetic properties for 5-HT could not be accurately 
determined since, after inhibition of endogenous MAO- 
A with 2 PM Ro 41-1049, the K,,, of this substrate for 
both proteins was >2 mM. 




(pmollmg (nM) mu’ (pmopmg 
prot.) prot.) 
MAO-A wild type 22.8 f 6.0 4.3 + 0.2 
MAO-(B36)A 25.7 f 7.6 4.1 f 0.2 
MAO-B wild type 17.7 f 1.3 6.0 f 0.5 
MAO-(A45)B 18.7 k 2.3 2.0 + 0.1 
Mean f S.E.M. of 3 experiments in duplicate. 
The tritiated selective inhibitors Ro 41-1049 and laza- 
bemide are useful radioligand probes for selectively de- 
termining the concentrations of the active centers of 
MAO-A and MAO-B, respectively [11,12,18]. Analysis 
of the saturation curve of [3H]Ro 41-1049 binding to 
MAO-A and MAO-(B36)A and of t3H]lazabemide to 
MAO-B and MAO-(A45)B did not reveal differences in 
the apparent KD values obtained (Table III). In the 
transfected cells MAO-A and MAO-(B36)A were found 
to be expressed to a similar extent, whereas the expres- 
sion of MAO-B was approximately 3 times higher than 
that of its (A45)B chimera. This accounts for the lower 
value of V,,, obtained for PEA deamination by MAO- 
(A45)B (see Table II). 
immunoblot analysis. As can be seen in Fig. 2A, the 
anti-MAO-A monoclonal antibody used recognized, 
besides the wild-type enzyme, the MAO-(B36)A but not 
the -(A45)B form, for which the intensity of the im- 
munoreactive band was virtually identical to that ob- 
served in untransfected or MAO-B-transfected cells. On 
the other hand, the anti-MAO-B lC2 monoclonal anti- 
bodies bound to the recombinant wild-type MAO-B, 
whereas no immunoreactivity was observed in untrans- 
fected or MAO-A-transfected cells. Interestingly, the 
antibody did not recognize the MAO-(A45)B nor the 
MAO-(B36)A proteins (Fig. 2B). This indicates that the 
immuno-determinant for the antibody is located at the 
region of the MAO-B N-terminal sequence where, in the 
hybrid, the two isoforms were joined together. 
3.2. Site-directed mutagenesis at Cys-397 of MAO-B 
As shown in Table IV, the potency and selectivity of 
various compounds in inhibiting the enzymatic activity 
of the chimeric mutant were not different in comparison 
to the respective wild-type MAO form. 
The expression of the clones was also verified by 
Table II 
Kinetic constants of PEA deamination by wild-type MAO-B and -A 
and by their N-terminal chimera 
In both MAOs the FAD is covalently attached to the 
apoproteins through a linkage between a cysteine resi- 
due (position 406 and 397 in MAO-A and -B, respec- 
tively, and the -CH, group in position 8a of FAD [19]. 
Substitution of Cys-397 of MAO-B with a neutral 
amino acid, i.e. Ala, resulted in the expression of inac- 
tive MAO-B. In several FAD-containing enzymes, the 
cofactor is covalently attached to the N-3 of a histidine 
residue (see e.g. [20] and examples cited therein). There- 
fore, we also investigated the effect of substituting the 
flavin-modified cysteine of MAO-B with histidine. Also 
in this case the expressed protein was catalytically inac- 
tive. By immunoblotting, both the site-directed mutated 
enzymes were recognized by the anti-MAO-B monoclo- 
nal antibody (Fig. 2B, lanes 6 and 7). 
K, V m.ix k c.it kc,JKm 
MM) (pmols’.mg (s-l) (M-‘s“) 
prot.) 
4. DISCUSSION 
MAO-B wild type 1.7 + 1.1 16.6 + 1.6 2.78 + 0.27 1.6 x lo6 
MAO-(A45)B 1.6 f 0.6 6.7 + 1.3 3.33 f 0.40 2.0 x lo6 
MAO-A wild type 154 f 12 13.1 + 1.6 3.07 f. 0.37 2.0 x lo5 
MAO-(B36)A 115f5 13.3 + 0.2 3.20 + 0.23 2.8 x 10’ 
Mean f S.E.M. of 34 experiments performed in duplicate. 
In the present study we have investigated some as- 
pects of the structure-activity relationships of the FAD 
binding sites of MAOs. At least two regions of the 
isoenzymes appear to be responsible for the binding of 
the cofactor: a non-covalent one, corresponding to the 
ADP-binding @/3 motif located at the N-terminal re- 
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Fig. 2. Immunoblot analysis of 293 cells transfected with the different 
constructs. (A) Anti-MAO-A antibodies: lane 1, wild-type MAO-B; 
2, MAO-(A45)B; 3, wild-type MAO-A; 4, MAO-(B36)A; 5, untrans- 
fected cells. (B) Anti-MAO-B antibodies: lane 1, wild-type MAO-A; 
2, MAO-(B36)A; 3, wild-type MAO-B; 4, MAO-(A45)B; 5, untrans- 
fected cells; 6, MAO-B Cys-397 + Ala; 7, MAO-B Cys-397 + His. 
gion [3]; a second, covalent one corresponding to a 
cysteine residue, to which FAD is bound through a 
thioether bridge [19], and located towards the C-termi- 
nal of the proteins. 
The results obtained by constructing N-terminal chi- 
meras of the two proteins indicate that the differences 
in the amino acid sequences existing within the ADP 
binding motif of MAO-A and MAO-B do not appear 
to play a role in the different specificity of the two 
isoenzymes for substrates and inhibitors. Therefore this 
domain might mainly play a structural role as a nuclea- 
tion center 15,211 and for stabilizing the proper enzyme 
conformation. On the other hand, if amino acids partic- 
ipating in the catalytic mechanism are present, they are 
likely identical and share the same position within the 
A and B form. The production of site-directed mutated 
FEBS LETTERS February 1993 
forms in this region will further help in clarifying the 
structure-function relationships of the non-covalent 
dinucleotide-binding domain of MAOs. In addition, 
our experiments indicate that the 9 amino acid exten- 
sion at the N-terminus of MAO-A, with respect to 
MAO-B [3], does not appear to influence the substrate 
selectivity. Therefore, other sequences have to be 
searched for, possibly among the less conserved ones, 
in order to determine the regions of the two enzymes 
that are responsible for the different topochemistry of 
their active sites. 
Regarding the covalent binding site for FAD, little is 
known about the coupling mechanism and whether this 
occurs as a co-translational or post-translational proc- 
ess. Autoflavination has been claimed to be responsible 
for the covalent attachment of FAD to MAOs [20]. The 
fact that the MAO-B enzymatic activity is lost upon 
substitution of cysteine at position 397 with an alanine 
is clearly an evidence for the requirement for a covalent 
FAD linkage with the apoprotein. In addition, the re- 
quirement for a cysteine is further stressed by the fact 
that this residue cannot be replaced by a histidine, the 
residue to which FAD is found to be covalently linked 
in other flavoproteins [ZO]. Whether the loss in activity 
is due to the fact that in MAO-B the FAD cannot be 
covalently coupled to residues other than cysteine or, 
alternatively, if this mutant still has covalently bound 
FAD, but the mutation markedly perturbs the protein 
conformation, cannot be assessed from the present ex- 
periments. Expression of the mutant protein and its 
purification in high amounts would be in fact manda- 
tory to assess whether covalent FAD is still present. 
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Table IV 
Inhibition of 5-HT and PEA deamination by various inhibitors in 293 cells transfected with wild-type and 
chimeric MAOs 
5-HT PEA 
MAO-A MAO-(B36)A MAO-B MAO-(A45)B 
wild type wild type 
Ro 19-6327 >10+ >10-5 6.9 + 2.1 x lo+ 4.7 * 2.0 x 1o-p 
Deprenyl 2.3 i: 1.0 x 1O-6 1.3 2 0.5 x 10-6 6.2 i: 2.1 x 1O-9 4.5 f 1.7 x lo+ 
Ro 41-1049 2.7 zt 0.4 x lo-* 3.3 + 0.3 x lo-* >10+ >10-5 
Harmaline 3.7 r 1.5 x 10-g 1.5 + 0.7 x 10-p >10-5 >lO_’ 
Cell homogenates were preincubated (15 min at 37°C) in the presence of 9 different concentrations of various 
inhibitors. MAO-A and MAO-B activities were then determined by incubation (10 min at 37°C) in the presence 
of 106 PM [‘%]5-HT and 1 PM [“‘CIPEA, respectively. Values are the mean f S.E.M. of 2-3 experiments 
performed in duplicate. 
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